|GENSPERA, INC. Patent applications|
|Patent application number||Title||Published|
|20160030589||Methods of Producing Cancer Compounds - Provided is a method for making the compound of Formula 1:||02-04-2016|
|20150265572||INJECTABLE CANCER COMPOSITIONS - Provided herein are therapeutic prodrug compositions which may be delivered to a patient via an injectable emulsion, comprising a therapeutic drug linked to a peptide that is efficiently and specifically cleaved by a selected protease associated with a cell proliferative disorder, including cancer cells, for example, prostate, liver or breast cancer cells, in a patient. Also provided herein are methods of treating cell proliferative disorders, including cancers, with the therapeutic prodrug compositions.||09-24-2015|
|20150238460||Methods and Compositions For Treating Hepatocellular Carcinoma - Provided herein are methods of treating subjects having tumors. For example, the invention relates to a method for treating subjects having hepatocellular carcinoma by administering an effective amount of a therapeutic prodrug.||08-27-2015|
|20090163426||TISSUE SPECIFIC PRODRUGS - The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drugs are activated and exert their toxicity. Sesquiterpene-γ-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.||06-25-2009|
|20080247950||Activation of peptide prodrugs by hK2 - The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.||10-09-2008|
Patent applications by GENSPERA, INC.